Is the determination of anti‐beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?

Hsieh, Kety; Knöbl, Paul; Rintelen, Claudia; Kyrle, Paul A.; Quehenberger, Peter; Bialonczyk, Christine; Partsch, Hugo; Lechner, Klaus; Pabinger, Ingrid

doi:10.1046/j.1365-2141.2003.04595.x

Cited by 14 publications

(8 citation statements)

References 40 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upper normal limits determined in our laboratory were 7.84 standard units (SU) for anti‐ β 2GPI IgG and 9.0 SU for anti‐ β 2GPI IgM as previously reported in detail by Hsieh et al. [15]. The normal range (95th percentile) was assessed in a control group of 113 healthy individuals (43 men, 70 women, mean age 46.7 years, IQR 38–52 years) without VTE.…”

Section: Methodsmentioning

confidence: 81%

“…In the present study we have used a commercial anti‐ β 2GPI assay which has been evaluated within the framework of the European Forum on Antiphospholipid Antibodies Standardization Group [26]. This assay has been tested for precision and reproducibility and has been used in a study with a large cohort of patients with a history of VTE, also including patients with antiphospholipid antibodies [15].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant

Zoghlami-Rintelen¹,

Vormittag²,

Sailer³

et al. 2005

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Summary. Background: Lupus anticoagulant (LA) is a strong risk factor of thrombosis. However, a subgroup of patients positive for LA is unaffected by thrombosis and currently no predictive markers are available to identify patients positive for LA at increased risk for thrombosis. Objective: The aim of the study was to investigate whether anti‐beta‐2‐glycoprotein I (anti‐β2GPI) or anticardiolipin antibodies (ACA) are associated with an increased risk of thrombosis in patients persistently positive for LA. Patients and methods: A cohort of 87 consecutive patients persistently positive for LA was investigated, 55 with and 32 without a history of thrombosis. Immunoglobulin G (IgG) and M (IgM) antibodies against β2GPI and cardiolipin were determined by enzyme‐linked immunoassay. Results: Patients positive for LA with thrombosis had significantly higher levels of anti‐β2GPI IgG (median 16.7 standard units, interquartile range 3.0–75.2, P = 0.002) and of ACA IgG (41.1 IgG phospholipid units per mL, 8.9–109.0, P = 0.002) than those without thrombosis (2.6, 1.4–7.9 and 9.7, 4.6–22.1, respectively). Levels of anti‐β2GPI IgM and ACA IgM did not differ significantly between LA patients with and without thrombosis (P = 0.25 and 0.12, respectively). Elevated anti‐β2GPI IgG was associated with an increased risk for thrombosis (OR = 4.0, 95% CI 1.2–13.1), especially for venous thromboembolism (OR = 5.2, 95% CI 1.5–18.0). Conclusions: Increased levels of anti‐β2GPI IgG were associated with thrombosis. We conclude that anti‐β2GPI IgG levels above normal predict an increased risk of thrombosis in patients persistently positive for LA.

show abstract

Section: Methodsmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant

Zoghlami-Rintelen¹,

Vormittag²,

Sailer³

et al. 2005

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…According to our study [102] and findings of other authors [103,104], anti-β 2 GPI are uncommonly detected in aPL negative patients with thrombosis. However, the detection of these antibodies might be useful in a small subset of patients with strong suspicion of APS and negative results for aPL.…”

Section: Clinical Studiesmentioning

confidence: 36%

Antigen Specificity and Clinical Relevance of Antiphospholipid Syndrome- Related Autoantibodies

Forastiero¹,

Martinuzzo

2005

CRR

View full text Add to dashboard Cite

The presence of antiphospholipid antibodies (aPL) combined with venous or arterial thrombosis, and/or obstetric complications defines the antiphospholipid syndrome (APS). Lupus anticoagulants (LA) and anticardiolipin antibodies (aCL) were the first described aPL. It has been shown that aPL, despite their name, are not directed against anionic phospholipids, as had previously thought, but are a part of a large family of autoantibodies against phospholipid-binding plasma proteins. The most important and relevant antigenic targets involved in APS are β 2 glycoprotein I (β 2 GPI) and prothrombin. However, an increasing number of other phospholipid-binding proteins with crucial functions in the regulation of blood coagulation and fibrinolysis are also targeted by APS-related autoantibodies. For clinical purposes, it is important to find which aPL markers has the best prognostic value. While it has been clearly demonstrated that LA and, to a lesser extent, aCL represent a risk for thrombosis, the role of antibodies directed against β 2 GPI, prothrombin as well as other targets is still uncertain and controversial. Data from a prospective study showed the presence of antibodies to prothrombin and/or β 2 GPI is a predictor of first or recurrent thromboembolic events in patients with LA and/or aCL. This review intends to highlight the antigen specificity and clinical relevance of APSrelated aPL.

show abstract

“…The determination of β2-GPI antibodies alone has a lower predictive value. 109 A search for aPL is usually indicated in younger otherwise healthy persons with thrombosis, while it is regarded as not indicated in asymptomatic patients without underlying disease. However, a meta-analysis has shown that in patients with aPL without underlying disease and previous thrombosis, the thrombotic risk is increased.…”

Section: Lpd/imd Causing Thrombosismentioning

confidence: 99%

Immune-Mediated Disorders Causing Bleeding or Thrombosis in Lymphoproliferative Diseases

Lechner

Pabinger

Obermeier

et al. 2014

Semin Thromb Hemost

Self Cite

View full text Add to dashboard Cite

Bleeding and thrombosis are important complications in patients with malignant lymphomas. They may be due to direct actions of the lymphoma, such as venous compression or bone marrow infiltration, but they may also be caused by paraneoplastic phenomena, which are immune-mediated in most of the cases. The most important paraneoplastic immune-mediated disorders in lymphomas causing bleeding are autoimmune thrombocytopenia, acquired hemophilia A and acquired von Willebrand syndrome. In addition, there are a variety of other less common immune-mediated bleeding conditions, such as acquired thrombasthenia, acquired factor X-, V-, XI-, XII-, or prothrombin deficiency. The presence of antiphospholipid antibodies is a rare condition predisposing to venous and arterial thrombosis and there are other very uncommon conditions, which predispose exclusively to arterial thrombosis such as hyperlipidemic xanthomatosis. Interestingly, there is hardly any correlation between the histological type and the aggressiveness of lymphoma and the type and prevalence of the immune-mediated conditions. Successful treatment of the underlying lymphoma is often associated with definite and sustained resolution of the immune-mediated disorder.

show abstract

Is the determination of anti‐beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?

Cited by 14 publications

References 40 publications

The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant

The presence of IgG antibodies against β2‐glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant

Antigen Specificity and Clinical Relevance of Antiphospholipid Syndrome- Related Autoantibodies

Immune-Mediated Disorders Causing Bleeding or Thrombosis in Lymphoproliferative Diseases

Contact Info

Product

Resources

About